

31 May 2017

INVESTOR UPDATE PRESENTATION

MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to provide the following investor update presentation, the purpose of which is to provide shareholders with an update on the Company’s activities and strategic outlook following the completion of the Harvest One Transaction last month.

The Company is well funded and is not looking to undertake a capital raising in the short term.

– ENDS –

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX: MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through its ~60% interest in TSX-V listed **Harvest One Cannabis Inc** (TSXV: HVST) and its 100% interest in Israeli research and development subsidiary, **PhytoTech Therapeutics Ltd**, both of which are strategically located in favourable jurisdictions with supportive regulatory frameworks in place.

About Harvest One Cannabis Inc.

Harvest One Cannabis Inc. (TSXV: HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation licence, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.



MMJ PhytoTech

Assets Streamlined and Positioned for Growth

MMJ PhytoTech Limited | Fully-Integrated Global Cannabis Company
May 2017 Investor Presentation



Disclaimer



ALL CURRENCY AMOUNTS ARE IN CAD UNLESS STATED OTHERWISE.

DISCLAIMER

This presentation has been prepared by PhytoTech Medical Limited (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

FUTURE MATTERS

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US DISCLOSURE

This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.

Executive Summary



Corporate Restructuring Complete

- MMJ PhytoTech Ltd. ('MMJ') completed corporate restructuring creating TSX-V listed Harvest One Cannabis ('Harvest' or 'HVST') (TSX-V:HVST)
 - MMJ vended Canadian subsidiary United Greeneries ('UG') together with Swiss subsidiary Satipharm ('SAT') for ~60% equity stake in HVST
 - HVST completed an oversubscribed C\$25M concurrent equity deal and commenced trading on April 28, 2017
- Restructuring greatly enhanced access to capital and provided MMJ shareholders strategic exposure to the rapidly growing Canadian cannabis markets and robust demand for cannabis-focused equities
- From announcement of restructuring MMJ's share price is up ~46%; YTD MMJ's share price is up ~63%

Assets Streamlined

- MMJ now has significant ownership in two well-financed, growth-oriented, streamlined cannabis-focused companies:
 - **~60% of HVST:** TSX-V listed cannabis and cannabis-based products company focused on supplying Canadian and international medical and recreational cannabis markets through two distinct operating brands:
 - United Greeneries: Canadian Licensed Producer with focus on large scale horticultural operations for the upcoming recreational market
 - Satipharm: International medical cannabis brand with focus on oral delivery technologies for strategic entry in emerging medical cannabis markets and the existing medical cannabis market in Canada
 - **100% of Phytotech Therapeutics ('PTL'):** private Israeli pure play biopharmaceutical company focused on developing and commercialising cannabis-based therapeutics. Strategic long-term arrangements with UG and SAT provide secure medical cannabis supply chain, a unique and crucial competitive advantage.

Positioned for Growth

- Phase 1 Expansion Plan currently underway at UG targeting the expansion of production capacity from to 7,500 kg/y from 1,000 kg/y
- European sales of Gelpell CBD capsules expected to expand significantly with SAT's targeted entry into select EU markets
- Two Phase 2 clinical trials currently underway at PTL: PTL101 to treat refractory epilepsy in pediatric patients; PTL201 to treat spasticity related symptoms of multiple sclerosis ("MS") patients

MMJ Post Restructuring



ASX: MMJ

60%
Equity Interest
(53.3M Shares)

100%



TSX-V listed cannabis company focused on supplying Canadian and international medical and recreational cannabis markets.



Large-Scale Cannabis Production for Recreational Market

- Canadian ACMPR Licensed Producer
- Multiple large-scale operations
- Targeting upcoming recreational market

Canadian Recreational Market



Int'l Medical Cannabis Brand, Oral Cannabis-based Supplement Sales

- Gelpell Capsule sales
- Focus on oral delivery technologies
- Targeting global medical cannabis markets

International Medical Cannabis Markets



Biopharmaceutical company, focused on cannabis-based therapeutics

- R&D / Clinical development
- Two drugs currently undergoing Phase 2 studies
- Pipeline of potential cannabis-based drugs

Global Pharmaceutical Market

- Post-restructuring, MMJ shareholders have exposure to the same assets but in an optimized ownership structure
- By creating HVST, MMJ eliminated the valuation discrepancy between UG and SAT and their peers in Canada by selling the assets to HVST at a value more inline with market prices in Canada
- Isolating PhytoTech at MMJ should have a positive impact on valuation as MMJ becomes a pure play biotech company with 53.3M HVST shares.
- Also, PhytoTech was often overshadowed by UG and SAT under original structure
- Additionally, the resulting entities are more streamlined and focused which will allow for better strategy execution going forward
- Another benefit of the restructuring is the separation of financing functions. MMJ does not have to dilute when HVST raises the considerable amount of capital it will need to raise
- There is significant overlap of Directors and management the main difference being increasing numbers of professionals being employed directly by HVST



MMJ and HVST at a Glance





Trading Statistics

(ASX : MMJ)

(TSX-V : HVST)⁽¹⁾

YTD Price / Volume:



Current Share Price:

A\$0.35

C\$0.70

YTD Price Performance:

+63%

-7%

YTD Avg Daily Volume:

~4,600,000

~209,000

Capitalization

Shares Out (Basic/FD):

204.8M / 252.0M

89M / 113.7M

Cash:

A\$8.4M

C\$20M

Market Cap:

A\$71.7M

C\$62.3M

Enterprise Value:

A\$63.3M

C\$42.3M

(1) HVST commenced trading April 28, 2017. HVST trading stats are from April 28, 2017 to present.

HVST Company Overview



- HVST is creating a unique dual strategy cannabis company
- Through HVST, MMJ shareholders will have significant exposure to two of the largest commercial opportunities in the global cannabis sector.



+



Cannabis Cultivation & Recreational Brand

United Greeneries is a Canadian ACMPR Licensed Producer and will be **Harvest One's** horticultural arm and recreational brand.

- ACMPR (MMPR) Licensed Producer Duncan Facility
- Current capacity of ~1,000 kg/year
- Immediate greenhouse expansion plan – targeting capacity growth to ~7,500 kg/year in 12 months (Phase I)
- 3-phase modular expansion up to ~50,000 kg/year
- ACMPR applicant Lucky Lake (~12,000 kg/year facility currently in security clearance stage)

Cannabis-based Health Products (Medical Cannabis)

Satipharm is specialised in the development and manufacturing of cannabis-based health products and will be the company's medical and health brand

- Flagship Gelpell® Microgel Capsules to lead growth
- Near-term growth from supplement sales in EU
- Mid-term growth from entry into regulated markets (Canada, Australia, etc.)
- Significant growth opportunities globally
- Global exclusive rights to Gelpell® on cannabis applications; Gelpell Phase 1
- Growing portfolio of delivery technology IP



HVST Recently Completed \$25M Equity Financing



C\$25M Equity Financing

Issued:	33,334,000 Subscription Receipts
Price:	C\$0.75/Sub Receipt
Unit:	1 share and ½ share purchase warrant with strike of \$1.00/share
Gross Proceeds:	C\$25,000,500

**Mackie Research Capital Corp.
Canaccord Genuity, Eight Capital, GMP Securities**

Indicative Use of Proceeds

MMJ Cash Consideration	\$2,000,000
Purchase of Duncan Facility	3,200,000
Acquisition of Genetic Material	1,350,000
Duncan Phase I Expansion	9,000,000
General Corporate & WC	9,450,000
Total Use of Proceeds	\$25,000,000

Following strong investor support, deal was upsized from C\$15M to C\$25M
Proceeds will finance capacity of dried cannabis buds of ~7,500 kg/year by the end of 2017



HVST World Class Duncan Facility



Location:	Duncan, BC – Vancouver Island
Ownership:	LT Lease to Harvest (7+ Years)
Size:	16,000 ft ²
Current Capacity:	App. 1,000kg dried cannabis flowers p.a.
Grow Plan:	31 distinct varieties
ACMPR Status:	ACMPR Cultivation License

16,000 ft² production facility and full quality control laboratory in Duncan, BC:

- 9,600 ft² cultivation area
- 2,000 ft² clean area
- Level 8 security vault
- Full in-house biochemical QA/QC laboratory
- Fully automated high-tech growing system
- Seasoned and experienced horticultural team, Head Grower employed with the Company since 2013

HVST World Class Duncan Facility



Figure 1: Duncan's State of the art cultivation area



Figure 2: Duncan Facility automated fertilizer system



Duncan Facility First Harvests

First two harvests completed in May 2017



Crops yielded approximately 100kg of OG Kush



Duncan Facility Expansion Plan

The Duncan expansion plan maximizes leverage to evolving cannabis market with flexible and timely capacity growth – total capacity of ~50,000 kg/y in 3 years

The 3-phase greenhouse expansion has a total estimated cost of \$51.5M

Targeting operating costs of ~\$1.8/g, the expanded capacity is expected to produce significant high-margin cash flow

**Phase I:
7,500 kg/y capacity + supporting infrastructure for all 3 phases**

- PF total capacity: 8,500 kg/y; Capex: \$9M
- Gross Area: 3a for greenhouse growing infrastructure, 2a for office + parking

**Phase II:
+17,500 kg/y capacity**

- PF total capacity: 26,000 kg/y; Capex: \$17.5M
- 7a greenhouses

**Phase III:
+25,000 kg/y capacity**

- PF total capacity: 51,000 kg/y; Capex: \$25M
- 10a greenhouses




Current Facility Expansion Lands

Phase	Expected Cost (\$M)	Add. Prod. Capacity (kg/y)	Gross Area (a)
I	\$9.0	7,500	3
II	\$17.5	17,500	7
III	\$25.0	25,000	10
Total	\$51.5	50,000	20



Lucky Lake Facility




Location:	Lucky Lake - SK
Ownership:	100% Owned by Harvest One
Size:	62,000 ft ² on 18- Acre site
Potential Capacity:	12,000 Kg/year
ACMPR Status:	Security clearance stage

62,000 ft² modern agricultural facility owned by Harvest One

- 40,000 ft² cultivation space across four interior bays
- 30 ft bay ceilings allow for vertical cultivation system
- Ample power and water and is situated adjacent to a CN rail line
- 18 acre property for expansion

- Based in Switzerland, Satipharm is a pioneer in the development and distribution of medical cannabis based pharmaceutical and nutraceutical products
- Flagship Gelpell® Microgel Capsule delivery technology overcomes bioavailability and consistency issues associated with oral delivery of cannabis-based products
- The Gelpell® Microgel Capsule is the only known product on the market with a pharmaceutical grade GMP (Good Manufacturing Product) production
- Satipharm's vision is to become a global leading company through the development and commercialisation of its signature Gelpell technology for cannabinoid based products
- Production of Gelpell Microgel Capsules commenced in May 2015, focusing on growth throughout regulated markets globally
- Currently preparing a significant marketing campaign to drive sales of 10 MG and 50 MG capsules throughout the EU
- Pharmaceutical Central Numbers (PZN codes) were obtained for 10MG and 50MG capsules in March 2017 enabling both products to be sold in any Pharmacy across Germany
- Further expansion plans include the introduction of other formulations including THC and importation into targeted international markets such as Canada and Australia



 Made in Switzerland




HVST Attractively Valued Against its Peers




- HVST is trading significantly below the industry average
- Expansion plans underway to significantly increase capacity


Equity Value (C\$M)⁽¹⁾



Enterprise Value (C\$M)




Current Capacity (kg/year)



HVST is trading at an attractive valuation

HVST Future Valuation Milestones



PhytoTech Therapeutics

Clinical Development: Oral Cannabinoid Products



PhytoTech Therapeutics ('PYL') is focused on cost-effective, fast-to-market oral prescription drugs

- Specifically, unique oral drugs based on major active cannabinoids

PYL have overcome the two major roadblocks to organic cannabis-based pharmaceuticals

- Secure, legal and scalable supply of raw input– MMJ's integrated "Farm to Pharma" supply chain will insure a sufficient, timely and standardized supply of raw cannabis plant material
- Standardized and efficient administration routes – MMJ has exclusive global licenses on two oral capsule formulations that overcome bioavailability and standardization issues associated with consumption of cannabis – Licensed from the Hebrew University and Gelpell®

Successful Phase 1 trial demonstrated definite advantages over Sativex^{RX}

Two Phase 2 Trials currently underway for two products:

- PTL101 - Oral drug to treat seizures of pediatric patients with refractory epilepsy
- PTL201 - Oral drug to treat spasticity of Multiple Sclerosis patients

Benefits of an Oral Capsule Over Oral Mucosal Spray

- Increased patient compliance
- No side effects like lesions, mouth ulcerations, pain and soreness of the oral mucosa
- Decreased administration frequency
- User friendly, no adverse taste, longer shelf life, lower cost
- Room temperature storage



PhytoTech Therapeutics (cont'd)



Successful Phase 1 Clinical Trial



Safety & PK Results of THC:CBD Formulations in Comparison to Sativex



Phase 1 Trial Overview	Phase 1 Trial Results
<ul style="list-style-type: none"> • Trial sponsored by Phytotech Therapeutics • Multi-arm, randomised, crossover study • 14/15 completers • Undertaken at Sourasky Medical clinic site • Pre-cursor to Phase 2 clinical trial for the treatment of pain and spasticity for MS 	<ul style="list-style-type: none"> • Demonstrable safety and tolerability profile with no significant side effects • Higher bioavailability (1.2-1.3x) of active compounds in comparison to GW Pharmaceuticals oromucosal spray – Sativex • Very rapid onset • 8 hours exposure time in the blood



Completion of the Phase 1 clinical trial shows a definite advantage over Sativex...





PhytoTech Therapeutics (cont'd)

Successful Phase 1 Clinical Trial



Safety & PK Results of Gelpell CBD Formulations



- Safe and tolerable profile with no significant side effects
- Consistent results
- 1.3 (134%) fold higher bioavailability of CBD 10 mg in comparison to 10 mg CBD in Sativex
- Perfect proportionality between CBD 10mg & 100mg
- 24 hours exposure time in the blood of CBD 100mg



PhytoTech Therapeutics (cont'd)

Phase 2 Trials to Commence Q4 2016 / Q1 2017



MMJ has commenced two Phase 2 Clinical Trials

Study	PTL201: MS Pain & Spasticity THC/CBD Capsule for relief of pain & spasticity due to MS
Study Description	A double-blind, randomized, placebo-controlled, parallel-group study of oral PTL201 THC/CBD capsules in subjects with symptoms of pain & spasticity due to MS
Drug Description	Gelpell® capsules containing THC and CBD
Objective	Safety, tolerability and efficacy
Subjects	~70 MS patients
Duration	Initiated Q2 2017
Cost	~US\$750K

PTL101: Pediatric Refractory Epilepsy CBD Capsule for reduction of seizures in pediatric refractory Epilepsy
Open-label, single-center clinical study of oral administration of PTL101 as an adjunctive treatment to refractory epileptic children
Gelpell® capsules containing highly purified, concentrated CBD
Safety, tolerability and efficacy
~15 pediatric patients with refractory epilepsy
Initiated Q1 2017 – completed YE 2017
~US\$710k



MMJ / Harvest One Board of Directors



ANDREAS GEDEON

Managing Director and
CEO MMJ & HVST

Mr. Gedeon, a former Officer in the German Navy, graduated with a Bachelor in Educational Science from the University of the German Federal Armed Forces Munich in 2000. He is an experienced entrepreneur and businessman with proven expertise in large-scale and HR intensive projects. His previous areas of business include media production and commercial construction.

As the founder of United Greeneries and Satipharm, Mr. Gedeon became Managing Director of MMJ Phytotech (ASX: MMJ) at time of the merger with Phytotech Therapeutics in July 2015. Mr. Gedeon currently oversees the global expansion strategy of the MMJ group.

PETER WALL

Chairman MMJ & HVST

Mr. Wall is a corporate lawyer based in Perth, Western Australia and is a Partner at one of Australia's leading corporate and commercial law firms. He graduated from the University of Western Australia in 1998 with a Bachelor of Laws and Bachelor of Commerce (Finance) and subsequently completed a Masters of Applied Finance and Investment with FINSIA (formerly the Securities Institute of Australia). Mr. Wall has a wide range of experience in all forms corporate and commercial law, with a particular focus on mergers and acquisitions, IPOs, back door listings and equity capital markets transactions.

JASON BEDNAR

Director MMJ & HVST

Mr. Bednar is a Chartered Accountant with more than 18 years of direct professional experience in the financial and regulatory management of companies listed on the TSX, TSX-V, American Stock Exchange and ASX.

He is currently the CFO and director of Canacol Energy Ltd., an oil and gas E&P company with an enterprise value of ~US\$650M. Mr. Bednar has significant public company management experience having held CFO positions at several international oil and gas companies, most notably as founding CFO of Pan Orient Energy Corp.

He previously sat on the board of directors of several internationally-focused E&P companies, including being the past Chairman of Gallic Energy Ltd. Mr. Bednar holds a Bachelor of Commerce degree from the University of Saskatchewan

WINTON WILLESEE, (CPA)

Director MMJ

Mr. Willesee is an experienced company director with a broad range of skills and experience in strategy, company development, corporate governance and corporate finance.

He has considerable experience with ASX listed companies and has been involved with many successful ventures

He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Governance Institute of Australia, a Member of the Australian Institute of Company Directors, a member of CPA Australia and a Chartered Secretary.

WILL STEWART

Director HVST

Mr. Stewart holds a Honours Bachelor of Arts degree from Wilfred Laurier University in Waterloo Ontario in Political Science. As a Managing Principal at Navigator and founding Principal at Ensign, he has earned the trust and respect of leaders in corporations, government and not-for-profit organizations for his expertise as a senior strategic public affairs advisor.

Mr. Stewart has demonstrated expertise in qualitative research, media relations, campaign planning and reputation management and recovery. He provides strategic planning, research and communications counsel to clients in a diverse variety of sectors, including aviation, energy, health care, and the emerging Canadian cannabis environment.

MMJ / Harvest One Management Team



ANDREAS GEDEON

Managing Director and
CEO MMJ & HVST

Mr. Gedeon, a former Officer in the German Navy, graduated with a Bachelor in Educational Science from the University of the German Federal Armed Forces Munich in 2000. He is an experienced entrepreneur and businessman with proven expertise in large-scale and HR intensive projects. His previous areas of business include media production and commercial construction.

As the founder of United Greeneries and Satipharm, Mr. Gedeon became Managing Director of MMJ Phytotech (ASX: MMJ) at time of the merger with Phytotech Therapeutics in July 2015. Mr. Gedeon currently oversees the global expansion strategy of the MMJ group.

DANIELA VASCHI

COS HVST

Ms. Vaschi is an Organizational Psychologist from the European Union with more than ten years of multidisciplinary experience, including over 6 years at the corporate level within global operations. She has a successful background in developing business structures from ground zero, as well as rebuilding infrastructure after mergers and acquisitions, downsizing and turnarounds.

Ms. Vasch is a versatile navigator of change management design and implementation, with a focus on organizational optimization. Her past work experience includes a track record of leading complex improvement initiatives in the automotive industry. She is an active member of the International Organization Development Association, performing an ongoing meta-analytic research on Emotional Intelligence.

GRAHAM WHITMARSH

COO HVST

Mr. Whitmarsh has experience in finance, capital and deal structure, health care, aviation, and technology at the CEO level in both the public and private sectors. Mr. Whitmarsh has held two of the most senior positions in the government of British Columbia: deputy minister of health, and deputy minister of finance and secretary to treasury board. He also brings experience within the medical marijuana industry as CEO for a start-up, providing initial leadership on behalf of a group of investors and consulting to the industry in Canada and the United States. Mr. Whitmarsh's previous experience includes president and CEO of Mercury Scheduling Systems and various other senior executive positions. He has served on numerous boards of directors, including public companies, not for profits and government committees, and holds a BSc (honours) in engineering from the University of Leeds.

NICK MALTCHEV

CTO HVST

Mr. Maltchev is a global executive with a passion for results and building great teams. He brings a mix of strategic thinking and deep technical knowledge and over 25 years of technology experience. He has been involved with the industry since 2004 and was an integral part of the Advanced Nutrients management team over a period of 12 years, holding several positions including information technology manager, COO and general manager. Mr. Maltchev holds a BBA degree, as well as other designations in project management, cybersecurity and computer science. He is also currently in the process of finishing an MBA in management information systems.

STANISLAV SOLOGUBOV

CEO Satipharm

Mr. Sologubov holds PhD in Economics from the State Technical University of Russia and also studied in the top international business schools like IMD, Switzerland and Open University, UK. Mr. Sologubov is an international sales and marketing executive with more than 15 years' experience in top global pharmaceutical and consumer goods companies including Johnson & Johnson, Bausch + Lomb and British American Tobacco. Mr. Sologubov has a wide range of experience in building and expanding international businesses, growing sales and achieving market leadership in more than 50 countries.

MMJ / Harvest One Management Team Continued..



CATHERINE HARVEY

CRO MMJ / HVST

Catherine Harvey is a highly experienced pharmaceutical industry executive, with an extensive corporate background, having worked for multiple pharmaceutical organizations both domestically and overseas. Most recently, Catherine held executive leadership positions including Director of Business Development and Corporate Affairs at Mundipharma Pty Limited and Business Development Manager at Norwegian Pharmaceutical company, Nycomed. Throughout her career to date, Catherine has established a strong track record in the implementation of successful commercialization strategies and strategic planning at senior management level.

Ms. Harvey holds a Bachelor of Science in Physiology, Pharmacology and Biochemistry and a Master of Business Law from the University of New South Wales

KWONG CHOO

CFO HVST

Mr. Choo has over 15 years of experience in senior financial roles and public company reporting experience. Having previously served as CFO with Russell Breweries Inc. (2013 – 2016), a TSX-V listed manufacturing company and CFO and Vice-president of finance and administration with Wex Pharmaceuticals Inc. (2007 – 2011), a TSX-listed biotechnology company. Mr. Choo earned a degree in management accounting from the Chartered Institute of Management Accountants, U.K., in 1990, and holds a Canadian Chartered Professional Accountant designation

COLIN CLANCY

VP Investor Relations HVST

Mr. Clancy brings over a decade of international experience through a variety of financial and business development roles. Most recently he was an integral member of the national Canadian medical marijuana team in Deloitte. Back in 2014 Colin was one of the first practitioners in Deloitte to focus on medical marijuana industry and led the marketplace activities in Western Canada. Deloitte is now the leading professional services provider in this space representing the majority of the public licensed producers. Prior to Deloitte, Colin was an Investor Relations Manger for several mining companies in Vancouver where he managed all corporate communication and investor relations activities for the companies. Prior to moving to Canada he worked within banking in both Ireland and Australia. Mr. Clancy also holds a degree in finance from the Dublin Institute of Technology.

DAPHNA HEFFETZ, PHD

CEO & Director of PhytoTech

Over 20 years' experience in establishing and growing Biotech and Medtech technology based companies. Her most recent position was Chief Executive Officer with Alon MedTech Ventures, an Israeli medical device and technology accelerator.

In 2000 she founded TransPharma Medical, a specialty pharmaceutical company, where she remained as CEO and Director of the Board until 2012. TransPharma became one of the most promising active transdermal drug delivery companies in the world. During her time at TransPharma she raised US\$34 million in three financing rounds from leading Israeli and International venture capital funds and brought over US\$50 million from collaborations with world leading pharmaceutical companies.

HAGIT SACKS, PHD

VP of R&D PhytoTech

Dr. Sacks has over 15 years of experience in pharmaceutical science and R&D

Hagit worked as the Director of Pharmaceutical R&D and the leader in two EU consortiums while at Nicast Ltd., a nanotechnology company developing implantable drug eluting medical devices made of electrospun polymeric nanofibers

From 2003-2012 she has held various leading positions at TransPharma Medical, a specialty pharmaceutical company. Her main responsibilities at TransPharma included directing research and innovative projects, managing the formulation laboratory and team, and leading the development of the company's first product in collaboration with Teva Pharmaceutical Industries.